Evidence Level
Phosphatidylserine has demonstrated efficacy in cortisol modulation and emerging evidence for stress resilience and cognitive enhancement. Monteleone et al. (1992) established foundational evidence that 800mg of phosphatidylserine blunts cortisol release during stress. Baumeister et al. (2008) extended this to a more practical 300mg dose, showing improved stress resilience and cognitive performance in individuals under induced stress. Hellhammer et al. (2014) further validated these findings in a larger study, demonstrating that phosphatidylserine-containing phospholipid complexes alleviate chronic stress symptoms.
For cognition, Kato-Kataoka et al. (2010) and Richter et al. (2013) provided randomized controlled trial evidence supporting phosphatidylserine's role in improving memory function in elderly individuals with cognitive complaints. The FDA recognizes a qualified health claim for phosphatidylserine, stating that its consumption may reduce the risk of dementia and cognitive dysfunction in the elderly, though this is based on very limited evidence.
Recent studies have explored additional applications. Bruton et al. (2021) conducted a systematic review and meta-analysis involving 216 participants, finding that 200-300mg/day of phosphatidylserine significantly reduced inattention symptoms in children with ADHD compared to placebo. Duan et al. (2025) demonstrated cognitive benefits, particularly in short-term memory, in older adults with mild cognitive impairment following supplementation. However, Friling et al. (2025) found no overall cognitive benefits in healthy children aged 8-12 years, though a subgroup with below-median baseline performance showed improved visuospatial memory.
These studies collectively highlight phosphatidylserine's potential across various domains of health and cognition, supported by robust evidence from multiple randomized controlled trials.